Antinucleosome Antibodies and Systemic Lupus Erythematosus

Thesis Submitted for partial fulfillment for the M. Sc. degree in Rheumatology and Rehabilitation

Presented by

Shimaa Mostafa Taha Goda M.B.; B.Ch. Faculty of Medicine, Cairo University

Under supervision of Prof. Dr. Geilan Abd El-moneim Mahmoud

Professor of Rheumatology and Rehabilitation Faculty of Medicine, Cairo University

Prof. Dr. Hala Fathy Shieba

Professor of Clinical Pathology Faculty of Medicine, Cairo University

Dr. Wael Sadek El-Sawy

Lecturer of Rheumatology and Rehabilitation Faculty of Medicine, Cairo University

Faculty of Medicine Cairo University 2010 مضادات النيوكلوسوم

و مرض الذئبه الحمراء رسالة مقدمه من الطبيبه

شيماء مصطفى طه جوده بكالوريوس الطب والجراحه العامه كلية الطب، جامعة القاهره توطئة للحصول على درجة الماجستير في الروماتيزم والتأهيل تحت اشراف

أ.د جيلان عبدالمنعم محمود استاذ الروماتيزم والتأهيل كلية الطب، جامعة القاهره

أ.د هاله فتحي شيبه استاذ الباثولوجيا الأكلينيكيه كلية الطب، جامعة القاهره

د. وائل صادق الصاوي مدرس الروماتيزم والتأهيل كلية الطب، جامعة القاهره

كلية الطب جامعة القاهره 2010

<u>Acknowledgement</u>

First and foremost, my deepest gratitude goes to Allah.

I would like to express my sincere appreciation and thankfulness to Dr. Gielan Abd El-maneim Mahmoud, Professor of Rheumatology and Rehabilitation, Cairo University for her keen interest in the progress of this work, and her support during reading and revising the manuscripts, Dr. Wael Sadek El-Sawy, Lecturer of Rheumatology and Rehabilitation, Cairo University, for his great help, his patience in reading and revising the manuscripts, and valuable ideas throughout the work, and Dr. Hala Fathy Sheiba, Professor of Clinical Pathology, Cairo University, for her great assistance and precious suggestions in the clinical pathology studies. I have been both honored and gratified working under their supervision.

Last but not least, it gives me a great pleasure to thank my family and my friends for their support, assistance and belief in my work and in me.

Dedication

To my family who inspired this work and is the spirit of my life, thanks a lot.

Shimaa

Abstract

- **Objective:** The aim of this study is to investigate the prevalence of antinucleosome antibodies in systemic lupus erythematosus and their association with disease activity and renal involvement.
- **Methods:** Fifty SLE patients of a mean age of 28.28 years and a mean disease duration of 5.46 years, were subjected to full history taking, full clinical examination, serum ANA, antidsDNA, and antinucleosome antibodies, with thirty healthy adults served as a control group.
- **Results**: A highly significant correlation was found between patients and control as regards the prevalence of antinucleosome antibodies. A non significant difference was detected between the presence of antinucleosome antibodies and the nephritis.
- **Conclusion:** Antinucleosome antibodies are present with a very high frequency in SLE but no association with disease activity or renal involvement could be detected
- **Keywords:** Systemic Lupus Erythematosus-Lupus nephritis-Antinucleosome antibodies-Disease activity-AntidsDNA.

LIST OF CONTENTS

CONTENTS	Page
INTRODUCTION	1
AIM OF WOTK	2
REVIEW OF LITERATURE	
Chapter 1: Lupus Nephritis	3
Chapter 2: Antinucleosome Antibodies	30
PATIENTS AND METHODS	45
RESULTS	57
DISCUSSION	69
CONCLUSION.	74
SUMMARY	75
REFERENCES	78
ARABIC SUMMARY	89

LIST OF FIGURES

No.	FIGURE	Page
1	Structure of Nucleosome	31
2	ROC curve	56
3	Classification of SLEDAI in the studied patients	60
4	Results of renal pathology	61

LIST OF TABLES

No.	TABLE	Page
1	World Health Organization Classification of lupus nephritis	12
2	World Health Organization (WHO) Nomenclature for Classifying the	
	Various Forms of Lupus Nephritis	13
3	International Society of Nephrology/Renal Pathology Society	
	Classification of Lupus Nephritis	14
4	The prognostic factors of lupus nephritis	29
5	The Revised Criteria for the diagnosis of Systemic Lupus	
	Erythematosus	45
6	Measurement of the activity of the disease using Systemic Lupus	
	Erethematosus Disease Activity Index (SLEDAI)	51
7	Descriptive features of patients included in the study	57
8	Frequency of clinical manifestations of patients	59
9	Autoantibodies results for the patients	59
10	Laboratory investigations results for the patients	58
11	Classification of SLEDAI in the studied patients	60
12	Renal pathology results in studied patients	61
13	The comparison between cases and controls as regards antinucleosome	
	antibodies	62
14	Relation between male and female as regards antinuleosome antibodies	
	results	62
15	Correlation between age and disease duration and antinucleosome	63

	antibodies results	
16	Correlation between different clinical manifestations and	
	antinucleosome antibodies results	63
17	Relation between antinucleosome antibodies and SLEDAI	64
18	Correlation between laboratory investigations and antinucleosome antibodies results.	65
19	Correlation between autoantibodies and antinucleosome antibodies results.	65
20	Relation between antinucleosome antibodies and cases had nephritis	66
21	Correlation between kidney functions and antinucleosome antibodies results	66
22	Relation between antidsDNA and patients had nephritis	66
23	Relation between antinucleosome antibodies results and grades of	
	nephritis	67
24	Relation between antinucleosome antibodies and active renal disease	68

LIST OF ABBREVIATIONS

ACR American Rheumatism Association criteria aCT Antichromatine antibodies AIH Autoimmune hepatitis ALT Alanine transaminase ANA Antinuclear antibodies ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-NCS Antinucleosome antibodies Anti-NCS Antinucleosome antibodies Anti-NCS Antinucleosome antibodies Astra Aspartate transaminase Bel-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate ESRD Endt antibodies Anti-Naviana Anti-Navia	ACLE	1 1 1
aCT Antichromatine antibodies AIH Autoimmune hepatitis ALT Alanine transaminase ANA Antinuclear antibodies ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti-nucleosome antibodies Anti-NCS Antinucleosome antibodies Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	ACLE	Acute cutaneous lupus erythematosus
AIH Autoimmune hepatitis ALT Alanine transaminase ANA Antinuclear antibodies ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
ALT Alanine transaminase ANA Antinuclear antibodies ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
ANA Antinuclear antibodies ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus Cr Creatinine CRP Creative protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
ANOVA Kruskal Wallis analysis of variance Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
Anti-AnN Antinucleosome antibodies Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-NCS Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
Anti PM-1 Anti polymyositis type 1 antbodies Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti-dsDNA Anti-dsDNA Anti-NCS Antinucleosome antibodies Anti-NCS Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
Anti SCL-70 Anti scleroderma 70 antibodies Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti-AnN	Antinucleosome antibodies
Anti-dsDNA Anti double stranded DNA Anti-NCS Antinucleosome antibodies Anti-Ncs Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti PM-1	Anti polymyositis type 1 antbodies
Anti-NCS Antinucleosome antibodies AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti SCL-70	Anti scleroderma 70 antibodies
Anti-Ncs Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti-dsDNA	Anti double stranded DNA
AST Aspartate transaminase Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti-NCS	
Bcl-2 B- cell lymphoma 2 bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Anti-Nes	Antinucleosome antibodies
bp Base pairs C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	AST	Aspartate transaminase
C3 Complement 3 C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Bcl-2	B- cell lymphoma 2
C4 Complement 4 C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	bp	Base pairs
C5-C9 Complement components Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	C3	Complement 3
Caspases Cysteine-aspartic proteases or cysteine-depended aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	C4	Complement 4
aspartic-directed proteases CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	C5-C9	Complement components
CCLE Chronic cutaneous lupus erythematosus Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Caspases	
Ch-50 Complement profile-total hemolytic complement. CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		<u> </u>
CLE Chronic lupus erythematosus CNS Central nervous system manifestations manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
CNS manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
manifestations Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
Cr Creatinine CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		Central nervous system manifestations
CRP C reactive protein CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		
CVA Cerebrovascular accident DIL Drug induced lupus DM Diabetes mellitus dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	Cr	Creatinine
DILDrug induced lupusDMDiabetes mellitusdsDNADouble stranded DNAELISAEnzyme linked immunosorbant assayEMElectrone microscopyESRErythrocyte sedimentation rate	CRP	
DMDiabetes mellitusdsDNADouble stranded DNAELISAEnzyme linked immunosorbant assayEMElectrone microscopyESRErythrocyte sedimentation rate	CVA	
dsDNA Double stranded DNA ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate	DIL	
ELISA Enzyme linked immunosorbant assay EM Electrone microscopy ESR Erythrocyte sedimentation rate		Diabetes mellitus
EM Electrone microscopy ESR Erythrocyte sedimentation rate		
ESR Erythrocyte sedimentation rate	ELISA	Enzyme linked immunosorbant assay
	EM	1 0
ESRD End stage renal disease	ESR	
	ESRD	End stage renal disease

FC	Fragment crystallizable
FC receptors	Fragment crystallizable receptors
GBM	Glomerular basement membrane
GN	Glomerulonephritis
HB	Heamoglobine
HRP	Horseradish peroxidase
HS	Heparan sulphate
HTN	Hypertention
IF	Immunofluorescence microscopy
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
ISN/RPS	International Society of Nephrology/Renal Pathology
	Society Classification of Lupus Nephritis
JCA	juvenile chronic arthritis
JSLE	Juvenile Systemic Lupus Erythematosus
LE	Lupus Erythematosus
LGN	Lupus glomerulonephritis
LM	Light microscopy
LSc	Localized scleroderma
MCTD	Mixed connective disease
PLT	Platelets
RA	Rheumatoid arthritis
RBC	Red blood cell
RNP	Ribonucleoprotein
ROC	Receiver operator characteristic
S.crt	Serum creatinine
SACLE	Subacute cutaneous lupus erythematosus
SACQ	Serologically Active Clinically Quiescent
SD	standard deviation
SLE	Systemic Lupus Erythematosus
SLEDAI	Systemic Lupus Erythematosus Disease Activity
	Index
Sm	Smooth muscle
SS	Sjögren's syndrome
SSc	Scleroderma
TLE	Tumid lupus erythematosus

TLRs	Toll like receptors
TNFα	Anti-tumor necrosis factor alpha
UV	Ultraviolet
WBC	White blood cell

Introduction

Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune disorder. It may affect the skin, joints, kidneys, and other organs. Normally, the immune system controls the body's defenses against infection. In SLE and other autoimmune diseases, these defenses are turned against the body and rogue immune cells attack tissues (*Steven*, 2005).

The pathologic findings of SLE occur throughout the body and are manifested by inflammation, blood vessel abnormalities that encompass bland vasculopathy and vasculitis, and immune-complex deposition. The best characterized pathology involves the kidney, which displays increases in mesangial cells and mesangial matrix (Inflammation, cellular proliferation, basement membrane abnormalities, and immune-complex deposition) (Weening et al., 2004).

Antibodies reacting with double strands DNA (dsDNA) are highly specific for SLE and have been found in approximately 50–80% of the patients. The presence of anti-dsDNA antibody is one of the 11 criteria for the classification of SLE and is important for clinical monitoring of the disease. (*Duzgun et al.*, 2007).

It has been proposed that the nucleosome is the principle antigen in the pathophysiology of SLE. The nucleosome (chromatin) is the native complex of DNA and histones. It consists of a 146 base pairs segment of DNA wrapped in two superhelical turns around an octameric core complex containing four pairs of the histone proteins H2A, H2B, H3, and H4. Its crystal structure has been

demonstrated. Nucleosomes become immunogenic under particular conditions. (Lugher et al., 1997).

Antinucleosome and anti-dsDNA antibodies were found in 74.5% and 78.4% (respectively), in patients with lupus nephritis, and antinucleosome antibodies were 31.4% in SLE patients lacking of anti-dsDNA antibodies (*Duzgun et al.*, 2007).

It could be demonstrated that antinucleosomes antibodies are detected in 84-88% of patients with lupus. It has been reported that anti-nucleosome immunoglobulin G antibodies are a more sensitive marker of SLE than anti dsDNA, and are almost exclusively found in lupus, scleroderma, and mixed connective tissue diseases. Furthermore, it has been shown that antinuclear autoantibodies complexed to nucleosomes can bind to heparin sulphate in the glomerular basement membrane (GBM) via the histone part of the nucleosome in SLE nephritis (*Berden et al.*, 1999).

Aim of work:

The aim of this study is to investigate the prevalence of antinucleosome antibodies in systemic lupus erythematosus and their association with disease activity and renal involvement.

CHAPTER 1

LUPUS NEPHRITIS

Definition

Lupus Erythematosus (LE) is a heterogeneous connective-tissue disease associated with polyclonal B-cell activation and is believed to result from the interplay of genetic, environmental, and hormonal factors (*Callen*, 2006).

Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system is misdirected against self-antigens, and the resulting immune effector pathways cause specific tissue damage. This damage is assumed to be initiated predominantly by immune complex deposition or direct autoantibody binding. Lupus nephritis is one of the most serious manifestations in SLE (*Fenton and Rekvig, 2007*).

Incidence:

It is well known that women, especially those of reproductive age, with a peak age of onset between the late teens and early 40s (*Joseph et al.*, 2007) are more susceptible to SLE compared to men, with a gender ratio of SLE patients of 10:1 (female: male). It is thought that sex hormones (such as estrogens) have a potent role in disease development. Studies had shown that estrogen can protect auto-reactive T lymphocytes from apoptosis, thus leading to a hyperactive production of autoantibodies by auto-reactive B cells. The role of prolactin in SLE had also been studied. Hyperprolactinemia is present in SLE patients of both sexes, with a correlation between prolactin concentrations and lupus activity. It is